TI - The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer
PT - Journal Article
DP - 2024
TA - EJMI
PG - 58-66
VI - 8
IP - 1
AID - 2023.36214 [doi]
4100 - https://dx.doi.org/10.14744/ejmi.2023.36214
SO - EURASIAN JOURNAL OF MEDICIAL INVESTIGATION,2024 8(1): 58